Enterin Inc.

Kainos Medicine, Inc. has begun a two-stage US Phase II study of an in-house developed novel Parkinson’s disease (PD) drug candidate KM-819, which the Korean biotech aims to develop as a disease modi

Just a couple of months after BioArctic AB trumpeted partner AbbVie Inc. 's plans to advance their Parkinson's drug ABBV-0805 into mid-stage trials this year, the US major has pulled the plug on a

The development of therapies for Parkinson’s disease should have been a triumph long ago for medical science. Degeneration of dopaminergic nerves in the central nervous system (CNS) was identified as

Denmark's mid-sized pharmaceutical company, Lundbeck Inc. , has moved its first-ever monoclonal antibody into clinical studies by taking the anti-alpha-synuclein antibody, Lu AF82422, into the clinic